For research use only. Not for therapeutic Use.
CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286)[1].
| Catalog Number | I044032 |
| CAS Number | 2144751-78-8 |
| Synonyms | 2-[(1R)-1-fluoroethyl]-5-[[6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methylimidazo[4,5-b]pyridin-1-yl]methyl]-1,3,4-oxadiazole |
| Molecular Formula | C19H17FN8O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17FN8O2/c1-10(20)18-26-25-15(30-18)8-27-11(2)24-17-14(27)6-12(7-21-17)13-4-5-28-16(13)19(29-3)22-9-23-28/h4-7,9-10H,8H2,1-3H3/t10-/m1/s1 |
| InChIKey | OENNTZBJPRRGFL-SNVBAGLBSA-N |
| SMILES | CC1=NC2=C(N1CC3=NN=C(O3)C(C)F)C=C(C=N2)C4=C5C(=NC=NN5C=C4)OC |
| Reference | [1]. Fused heterocyclic compounds. Patent JPWO2017188374A1. |
